Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.

Frontiers in immunology - 1 Jan 2018

Bandara Geethani, Muñoz-Cano Rosa, Tobío Araceli, Yin Yuzhi, Komarow Hirsh D, Desai Avanti, Metcalfe Dean D, Olivera Ana

Abstract excerpt

Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tissues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis are limited, thus exploration of novel pharmacological targets that reduce MC burden is desirable. Since increased generation of the lipid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrazines

Share to Mast Cells

Share to Mastocytosis

Share to Phosphotransferases (Alcohol Group Acceptor)

Share to Pyrazoles

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 29643855
DOI: 10.3389/fimmu.2018.00631
PMCID: PMC5883065

Genes

KIT
SPHK1
SPHK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.PMID 29643855Read ↗

New Insights into the Pathogenesis of Systemic Mastocytosis.Semantic proximity Read ↗

Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.Semantic proximity Read ↗

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.Semantic proximity Read ↗

KIT mutations in mastocytosis and their potential as therapeutic targets.Semantic proximity Read ↗

Mast cell-deficient Kit(W-sh) "Sash" mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cells.Semantic proximity Read ↗

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Semantic proximity Read ↗

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.Semantic proximity Read ↗

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.Semantic proximity Read ↗

KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progressionSemantic proximity Read ↗

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.